Stryker Corporation $SYK Stock Bought by Howland Capital Management LLC

Howland Capital Management LLC boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 1.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 126,732 shares of the medical technology company’s stock after purchasing an additional 2,180 shares during the period. Stryker accounts for about 1.2% of Howland Capital Management LLC’s holdings, making the stock its 20th largest position. Howland Capital Management LLC’s holdings in Stryker were worth $35,012,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mitchell Mcleod Pugh & Williams Inc. boosted its holdings in shares of Stryker by 1.2% in the 1st quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company’s stock worth $880,000 after purchasing an additional 31 shares during the period. Community Bank & Trust Waco Texas increased its position in shares of Stryker by 2.3% during the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock valued at $439,000 after purchasing an additional 31 shares during the last quarter. Cornerstone Financial Management LLC raised its holdings in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after buying an additional 31 shares during the period. NWF Advisory Services Inc. raised its holdings in Stryker by 2.3% during the 2nd quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after buying an additional 33 shares during the period. Finally, Harold Davidson & Associates Inc. lifted its position in Stryker by 0.4% in the first quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock worth $2,848,000 after buying an additional 34 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In related news, insider Dylan Crotty sold 441 shares of Stryker stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This trade represents a 6.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Debra King sold 826 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 351,267 shares of company stock worth $118,197,701 in the last 90 days. 4.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

SYK has been the subject of several recent analyst reports. Citizens Jmp dropped their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. TD Cowen lowered their target price on shares of Stryker from $355.00 to $298.00 and set a “hold” rating for the company in a report on Tuesday, September 22nd. Sanford C. Bernstein restated a “market perform” rating on shares of Stryker in a report on Wednesday, October 7th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $317.00 price target on shares of Stryker in a research note on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $369.00.

Stryker Stock Performance

Shares of Stryker stock opened at $307.41 on Friday. The stock’s fifty day moving average is $295.86 and its two-hundred day moving average is $311.96. The company has a market capitalization of $117.91 billion, a PE ratio of 31.86, a price-to-earnings-growth ratio of 1.92 and a beta of 0.78. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 52 week low of $267.00 and a 52 week high of $389.33.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the company earned $3.13 earnings per share. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 14.93 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.